Search Page

1

Cite

Share

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.

Cite

Share

2

Cite

Share

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.

Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. Rodbard HW, et al. Diabetes Care. 2019 Dec;42(12):2272-2281. doi: 10.2337/dc19-0883. Epub 2019 Sep 17. Diabetes Care. 2019. PMID: 31530666 Clinical Trial.

Cite

Share

3

Cite

Share

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Pfeffer MA, et al. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. N Engl J Med. 2015. PMID: 26630143 Free article. Clinical Trial.

Cite

Share

4

Cite

Share

Natural Products: Optimizing Cancer Treatment through Modulation of Redox Balance.

Rijo P, Pešić M, Fernandes AS, Santos CN. Rijo P, et al. Among authors: pesic m. Oxid Med Cell Longev. 2020 Jun 2;2020:2407074. doi: 10.1155/2020/2407074. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32566077 Free PMC article. No abstract available.

Cite

Share

5

Cite

Share

Incidence trend of type 1 diabetes mellitus in Serbia.

Vojislav C, Natasa R, Milica P, Slobodan A, Radivoj K, Danijela R, Sasa R. Vojislav C, et al. Among authors: milica p. BMC Endocr Disord. 2020 Mar 9;20(1):34. doi: 10.1186/s12902-020-0504-y. BMC Endocr Disord. 2020. PMID: 32151244 Free PMC article.

Cite

Share

6

Cite

Share

Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment.

Neto I, Domínguez-Martín EM, Ntungwe E, Reis CP, Pesic M, Faustino C, Rijo P. Neto I, et al. Among authors: pesic m. Pharmaceutics. 2021 Jun 2;13(6):825. doi: 10.3390/pharmaceutics13060825. Pharmaceutics. 2021. PMID: 34199531 Free PMC article.

Cite

Share

7

Cite

Share

Potential of Natural-Based Anticancer Compounds for P-Glycoprotein Inhibition.

Dinić J, Podolski-Renić A, Jeremić M, Pešić M. Dinić J, et al. Among authors: pesic m. Curr Pharm Des. 2018;24(36):4334-4354. doi: 10.2174/1381612825666190112164211. Curr Pharm Des. 2018. PMID: 30648503 Review.

Cite

Share

8

Cite

Share

Advanced technological tools to study multidrug resistance in cancer.

Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Suárez Korsnes M, Vaclavikova R, Assaraf YG, Pešić M. Andrei L, et al. Among authors: pesic m. Drug Resist Updat. 2020 Jan;48:100658. doi: 10.1016/j.drup.2019.100658. Epub 2019 Oct 17. Drug Resist Updat. 2020. PMID: 31678863 Review.

Cite

Share

9

Cite

Share

Protein kinases as targets for developing anticancer agents from marine organisms.

Qiao G, Bi K, Liu J, Cao S, Liu M, Pešić M, Lin X. Qiao G, et al. Among authors: pesic m. Biochim Biophys Acta Gen Subj. 2021 Jan;1865(1):129759. doi: 10.1016/j.bbagen.2020.129759. Epub 2020 Oct 8. Biochim Biophys Acta Gen Subj. 2021. PMID: 33038451 Review.

Cite

Share

10

Cite

Share

In vitro biomimetic models for glioblastoma-a promising tool for drug response studies.

Stanković T, Ranđelović T, Dragoj M, Stojković Burić S, Fernández L, Ochoa I, Pérez-García VM, Pešić M. Stanković T, et al. Among authors: pesic m. Drug Resist Updat. 2021 Mar;55:100753. doi: 10.1016/j.drup.2021.100753. Epub 2021 Feb 20. Drug Resist Updat. 2021. PMID: 33667959 Free article. Review.

Cite

Share